Amyloidosis refers to a range of protein misfolding disorders that can cause organ dysfunction through progressive fibril deposition. Cardiac involvement often leads to significant morbidity and mortality and increasingly has been recognized as an important cause of heart failure. The two main forms of cardiac amyloidosis, light chain (AL) and transthyretin (ATTR) amyloidosis, have distinct mechanisms of pathogenesis. Recent insights have led to the development of novel pharmacotherapies with the potential to significantly impact each disease. This review will summarize the preclinical and clinical data for these emerging treatments for AL and ATTR amyloidosis.

淀粉样变性是指一系列蛋白错误折叠疾病，这些疾病可通过进行性原纤维沉积而引起器官功能障碍。心脏受累通常会导致严重的发病率和死亡率，并且越来越多地被认为是心力衰竭的重要原因。心脏淀粉样变性的两种主要形式，轻链（AL）和运甲状腺素蛋白（ATTR）淀粉样变性，具有独特的发病机理。最近的见解导致了新的药物疗法的发展，其可能显着影响每种疾病。这篇综述将总结这些新兴的AL和ATTR淀粉样变性治疗的临床前和临床数据。